
Chinese General Practice ›› 2026, Vol. 29 ›› Issue (14): 1946-1952.DOI: 10.12114/j.issn.1007-9572.2024.0550
• Research Methodology & Tools • Previous Articles
Received:2024-11-10
Revised:2025-01-01
Published:2026-05-15
Online:2026-04-14
Contact:
BAN Chengjun
通讯作者:
班承钧
作者简介:作者贡献:
刘嘉玲负责整体文章构思、查阅文献及文章撰写;班承钧负责最终版本修订,对文章整体负责。
基金资助:CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2024.0550
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
中华人民共和国中央人民政府.健康中国行动(2019—2030年)国发〔2019〕13号[EB/OL].(2019-07-15)[2024-12-20].
|
| [5] |
Clinical Trials Transformation Initiative. Decentralized clinicaltrials[EB/OL].(2018-12-26)[2024-12-20].
|
| [6] |
U.S. Food and Drug Administration. Guidance on conduct of clinical trials of medical products during COVID-19 public health emergency[EB/OL].[2024-12-20].
|
| [7] |
European Medicines Agency.Recommendation paper on decentralised elements in clinical trials[EB/OL].(2022-12-13)[2024-12-20].
|
| [8] |
U.S. Food and Drug Administration.Conducting clinical trials with decentralized elements[EB/OL].(2024-09-18)[2024-12-20].
|
| [9] |
国务院办公厅.国务院办公厅关于促进"互联网+医疗健康"发展的意见(国办发〔2018〕26号)[EB/OL].(2018-04-28)[2024-12-20].
|
| [10] |
国家药监局药审中心.《新冠肺炎疫情期间药物临床试验管理指导原则(试行)》(2020年第13号)[EB/OL]. (2020-07-14)[2024-12-20].
|
| [11] |
国家药监局药审中心.《患者报告结局在药物临床研发中应用的指导原则(试行)》(2021年第62号)[EB/OL]. (2021-12-27)[2024-12-20].
|
| [12] |
《远程智能临床试验专家共识》编写专家组, 上海市药学会药物临床研究专业委员会, 药物信息协会中国数字健康社区. 远程智能临床试验专家共识[J]. 中国新药与临床杂志, 2022, 41(7): 385-392. DOI: 10.14109/j.cnki.xyylc.2022.07.01.
|
| [13] |
国家药监局药审中心关于发布《以患者为中心的药物临床试验设计技术指导原则(试行)》《以患者为中心的药物临床试验实施技术指导原则(试行)》《以患者为中心的药物获益-风险评估技术指导原则(试行)》的通告(2023年第44号)[EB/OL]. (2023-07-28)[2024-12-20].
|
| [14] |
泰格医药. 2023数字化/去中心化临床试验行业发展现状调研分析报告[EB/OL]. (2024-01-03)[2024-12-20].
|
| [15] |
|
| [16] |
姚晨, 王斌, 阎小妍. 数字化转型引领临床试验变革:提升质量与效率[J]. 数字医学与健康, 2024, 2(2): 63-69. DOI: 10.3760/cma.j.cn101909-20231120-00066.
|
| [17] |
陈一飞, 董文彬, 孙搏, 等. 去中心化药物临床试验实施模式和合规关注点讨论[J]. 中国新药与临床杂志, 2023, 42(8): 507-513. DOI: 10.14109/j.cnki.xyylc.2023.08.06.
|
| [18] |
|
| [19] |
Medidata. Medidata Insights on Clinical Trial Enrollment White Paper[EB/OL]. (2022-09-01)[2024-12-20].
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
TransCelerate Biopharma, INC.What do clinical trial participants want?[EB/OL].[2024-12-20].
|
| [28] |
邢倩, 何达, 符雨嫣, 等. 数字健康技术评估与应用的国际经验[J]. 健康发展与政策研究, 2024, 27(1): 29-35.
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
崔欢欢, 唐凌, 崔灿, 等. 在罕见病药物临床研发中应用去中心化临床试验的考虑[J]. 罕见病研究, 2024, 3(2): 175-180.
|
| [33] |
|
| [34] |
周凤, 甘晨曦, 徐亚文, 等. 去中心化临床试验应用现状[J]. 南昌大学学报(医学版), 2023, 63(2): 88-92. DOI: 10.13764/j.cnki.ncdm.2023.02.017.
|
| [35] |
|
| [36] |
|
| [37] |
泰格医药.Global Regulatory Handbook of Decentralized Clinical Trials[EB/OL].[2024-12-20].
|
| [38] |
U.S. Food and Drug Administration. Decentralized Clinical Trials for Drugs, Biological Products, and Devices[EB/OL]. (2023-05-01)[2024-12-20].
|
| [39] |
国家药监局药审中心.《在罕见疾病药物临床研发中应用去中心化临床试验的技术指导原则》的通告(2024年第25号)[EB/OL]. (2024-05-28)[2024-11-14].
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
冯致远, 李子孝, 王春娟. 数字健康在脑血管病领域的应用及未来发展趋势[J]. 中国卒中杂志, 2024, 19(6): 607-612.
|
| [46] |
|
| [47] |
毛敏, 谢湘梅, 严婷, 等. 远程医疗在慢性阻塞性肺疾病健康管理中的应用进展[J]. 循证护理, 2024, 10(5): 826-830.
|
| [48] |
|
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
廖茜雯, 姚晨, 张军, 等. 真实世界数据和证据在我国临床决策中的应用现状[J]. 中国食品药品监管, 2023(10): 24-31. DOI: 10.3969/j.issn.1673-5390.2023.10.003.
|
| [53] |
刘建平. 循证中医临床试验的机遇、挑战与对策[J]. 现代中医临床, 2024, 31(2): 1-5.
|
| [54] |
赵国桢, 郭诗琪, 庞华鑫, 等. 基于中医临床诊疗数据的真实世界及人工智能研究思路与挑战[J]. 中医杂志, 2023, 64(21): 2170-2175. DOI: 10.13288/j.11-2166/r.2023.21.002.
|
| [55] |
国家药监局药审中心.《用于产生真实世界证据的真实世界数据指导原则(试行)》的通告(2021年第27号)[EB/OL]. (2021-04-13)[2024-12-20].
|
| [56] |
孙搏, 陈一飞, 李刚. 远程智能临床试验的监管策略分析[J]. 中国新药与临床杂志, 2024, 43(6): 436-441. DOI: 10.14109/j.cnki.xyylc.2024.06.08.
|
| [57] |
卜丽娟, 江柯萱, 周吉银. 去中心化临床试验的挑战、对策及伦理审查要点[J]. 中国医学伦理学, 2024, 37(4): 399-407.
|
| [58] |
吴晓蕾, 史梦龙, 张晨瑶, 等. 以患者为中心药物研发相关概念介绍[J]. 中国循证医学杂志, 2023, 23(12): 1472-1477.
|
| [59] |
|
| [60] |
|
| [61] |
|
| [62] |
杨秀巧, 文萍, 林泓, 等. 中国临床试验受试者隐私权保护的相关问题及解决策略[J]. 中国当代医药, 2023, 30(3): 140-144.
|
| [63] |
|
| [64] |
葛永彬, 董剑平, 邵亚光. 去中心化临床试验中的供应商合规管理[J]. 中国食品药品监管, 2023(12): 188-195.
|
| [65] |
|
| [66] |
|
| [1] | PENG Jun, DING Jinglin, HAO Chenye, WU Cheng, ZHU Ronghui, GU Chunguang, GUAN Wenqi, WAN hui. A Randomized Controlled Study Comparing the Effectiveness of Online and Offline Training on Improving Digital Health Literacy among the Elderly [J]. Chinese General Practice, 2026, 29(10): 1348-1353. |
| [2] | DONG Kecheng, ZHANG Xingxia, YUAN Yongqing, JIANG Jie. A Comparative Analysis of the Current Situation and Influencing Factors of Digital Health Literacy among County Residents [J]. Chinese General Practice, 2026, 29(10): 1340-1347. |
| [3] | LIU Yan, YUAN Yanling, LING Rong, WANG Lanyun, SUN Li. Scoping Review of Telemedicine Application in Cardiac Rehabilitation for Coronary Heart Disease Patients [J]. Chinese General Practice, 2025, 28(36): 4640-4647. |
| [4] | WU Xinyi, ZHANG Yongze, YANG Chenghu, WU Xiaoyuan. Demand Analysis of Diabetes Primary Healthcare and Prevention Integration Services in the Context of Digital Health [J]. Chinese General Practice, 2024, 27(31): 3958-3965. |
| [5] | TANG Zhijie, SUN Guozhen, GAO Min, WANG Jie, BAO Zhipeng, YANG Gang, WANG Lin, WANG Qin. Reasons for Refusal of Exercise Rehabilitation in Patients after Radiofrequency Ablation of Atrial Fibrillation in the Context Digital Medical Care: a Qualitative Research [J]. Chinese General Practice, 2024, 27(18): 2218-2224. |
| [6] | SHI Bowen, MA Huimin, PAN Yanzhi, MA He, YANG Chen, XIONG Juyang. Bibliometric Analysis of Advances in mHealth Technology Application in Chronic Disease Management [J]. Chinese General Practice, 2024, 27(04): 485-492. |
| [7] | WANG Jun, WU Jiafei, WANG Yijing, ZHENG Boyue, WANG Yu, JIANG Chuanyan, LI Hui. Efficacy and Prognostic Effect of Daratumumab-based Chemotherapy Regimen in Multiple Myeloma: a Real-world Study [J]. Chinese General Practice, 2023, 26(18): 2256-2262. |
| [8] | YANG Hui. Prevention and Control of the COVID-19 Epidemic and Management of Chronic Disease [J]. Chinese General Practice, 2023, 26(07): 780-782. |
| [9] | ZHANG Haicheng, YU Xinyan, WANG Hongyu, XUE Tao, LIAO Xiaoyang, FAN Yongmei, ZHANG Qinghong. Discussion on the Difficulties and Bottlenecks in the Management of Remote ECG-based Screening for Cardiovascular Disease Risk in Hierarchical Diagnosis and Treatment [J]. Chinese General Practice, 2023, 26(05): 525-531. |
| [10] | YI Huijie, LIAO Xinyi, PI Mengyuan, XU liyue, ZHANG Chi, DONG Xiaosong, HAN Fang. Development of a New Remote Diagnosis and Treatment Model for Obstructive Sleep Apnea: a Non-inferiority Randomized Controlled Trial Protocol [J]. Chinese General Practice, 2023, 26(03): 380-385. |
| [11] | YU Xinyan, ZHAO Xudong, ZHAO Xiaoye, LIU Haipeng, JIANG Qingru, ZHANG Haicheng. Diagnostic Accuracies of Three Schemes for Arrhythmia Screening Using a Wearable Single-lead ECG Monitoring System: a Real-world Community-based Study [J]. Chinese General Practice, 2023, 26(02): 192-200. |
| [12] | Hanwen YANG, Yaoxian WANG, Qiaoru WU, Jiale ZHANG, Runze YAN, Xiaona WANG, Zhen WANG, Weiwei SUN. Efficacy and Safety of Xiezhuoxiaozheng Therapy in Diabetic Kidney Disease: a Clinical Study [J]. Chinese General Practice, 2022, 25(26): 3252-3257. |
| [13] | Binyang HUANG, Xiaorui LIU, Luping YANG, Mengxiao LI, Shuang ZHENG, Anren ZHANG. Efficacy of Traditional Bigu Health-preserving Regimen in Healthy People: a Crossover Trial Using Real-world Data [J]. Chinese General Practice, 2022, 25(17): 2090-2095. |
| [14] | Chunguo XING, Yingqiu XIA, Danyun WU, Yunxia LIAO, Ning ZHAO. The Informatization Construction and Use of Primary Health Institutions in Jiangsu Province [J]. Chinese General Practice, 2022, 25(16): 2008-2013. |
| [15] | Liping CUI, Kun HU, Haoce HUANG, Ning DENG, Jia WEN, Lisen YANG, Yuexia ZHAO. Effect of Cognitive-behavioral Change Model-based Online Health Education in Hypertension Management [J]. Chinese General Practice, 2022, 25(16): 1984-1989. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||